Drugs / amycretin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05369390 | May 2022 → Jan 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-05 | Novo Nordisk A/S | Results Novo Nordisk’s investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes - presented at ADA 2026 novonordisk.com ↗
A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to placebo, with up to 89.1% achieving HbA1C below 7%1 |
| 2025-11-25 | Novo Nordisk A/S | Results Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes novonordisk.com ↗
Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. |
| 2025-01-24 | Novo Nordisk A/S | Results Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity novonordisk.com ↗
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration. |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amycretin | “Amycretin is a novel, single-molecule GLP-1 receptor and amylin receptor agonist.” PMID 40550229 ↗ Jun 2025 |
| Action | Activate | “GLP-1 receptor and amylin receptor agonist” PMID 40550229 ↗ Jun 2025 |